Recent Developments in Vaccines against Respiratory Pathogens
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".
Deadline for manuscript submissions: 31 July 2024 | Viewed by 126
Special Issue Editor
Interests: mucosal immunology; influence of human microbiome on immune system development; host-pathogen interactions; development of new generation innovative (nanotechnology based) mucosal (intranasal and oral) vaccine delivery platforms; vaccine delivery platforms evaluation in animal models (pig, poultry, rodents)
Special Issue Information
Dear Colleagues,
Respiratory diseases are responsible for millions of deaths annually, with most being caused by respiratory tract infections. The most viable way to mitigate these diseases is through vaccination. Vaccine formulations and policies are constantly updated to provide protection against severe respiratory diseases as RNA viruses continue to evolve. For instance, COVID-19 mRNA vaccines were recommended in the USA in 2022, but these vaccines are being updated to protect against SARS-CoV-2 variants. Specifically, the FDA has approved a monovalent Omicron XBB.1.5 COVID-19 vaccine which targets the current circulating variant. A recently developed COVID–influenza combination vaccine entered Phase 3 clinical trials in 2023. This vaccine was developed to offer dual protection against both influenza and COVID-19 in a single shot, increasing protection during the influenza season. Additionally, in 2023, a maternal RSV vaccine was also approved that is specifically designed to protect women who are 32–36 weeks pregnant during the RSV season. These are all examples of improvements in vaccine safety and effectiveness.
We invite scholars developing or evaluating novel vaccine candidates against respiratory pathogens to submit their work to this Special Issue by July 2024.
Prof. Dr. Renukaradhya J. Gourapura
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine development
- respiratory diseases
- COVID-19 vaccine
- influenza vaccine
- RSV vaccine
- respiratory tract infection prevention
